UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 191

Sortiert nach

Targeting basal-like breast cancers

Current drug targets, 2012-11, Vol.13 (12), p.1510

2012

Link zum Volltext

Verfügbarkeit prüfen

399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study

European journal of cancer (1990), 2014-11, Vol.50, p.128-128

2014

Link zum Volltext

Verfügbarkeit prüfen

Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial

Annals of oncology, 2018-10, Vol.29, p.viii70-viii70

2018

Link zum Volltext

Verfügbarkeit prüfen

2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies

European journal of cancer (1990), 2015-09, Vol.51, p.S548-S548

2015

Link zum Volltext

Verfügbarkeit prüfen

376 Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study

European journal of cancer (1990), 2012-11, Vol.48, p.115-115

2012

Link zum Volltext

Verfügbarkeit prüfen

375 Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy

European journal of cancer (1990), 2012-11, Vol.48, p.114-115

2012

Link zum Volltext

Verfügbarkeit prüfen

PP 26 IGF-1R signaling in ER+ and triple negative breast cancer - a potential target for therapy?

European journal of cancer (1990), 2011, Vol.47, p.S16-S16

2011

Link zum Volltext

Verfügbarkeit prüfen

P068 Sequencing to identify potential targets of resistance to primary therapy

Breast (Edinburgh), 2015-03, Vol.24, p.S50-S50

2015

Link zum Volltext

Verfügbarkeit prüfen

P024 Navigating genomic landscape: PI3KSIGNALING algorithm for rational combination in precision medicine

Breast (Edinburgh), 2015-03, Vol.24, p.S34-S34

2015

Link zum Volltext

Verfügbarkeit prüfen

P049 Genomic landscape of the PI3K pathway and cell-cycle pathway in ER+ BC: a treatment strategy

Breast (Edinburgh), 2015-03, Vol.24, p.S43-S43

2015

Link zum Volltext

Verfügbarkeit prüfen

PP 25 Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer

European journal of cancer (1990), 2011, Vol.47, p.S17-S17

2011

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

The New England journal of medicine, 2005-10, Vol.353 (16), p.1659-1672

2005

Link zum Volltext

Verfügbarkeit prüfen

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

The New England journal of medicine, 2001-03, Vol.344 (11), p.783-792

2001

Link zum Volltext

Verfügbarkeit prüfen

S2 Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank

European journal of cancer supplements, 2007, Vol.5 (8), p.5-5

Leyland-Jones, B

2007

Link zum Volltext

Verfügbarkeit prüfen

Synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and β-ionylideneacetamidobenzoates with retinoidal activity

Journal of medicinal chemistry, 1998-07, Vol.41 (16), p.3062-3077

1998

Link zum Volltext

Verfügbarkeit prüfen

S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer

Breast (Edinburgh), 2009, Vol.18, p.S11-S11

2009

Link zum Volltext

Verfügbarkeit prüfen

229 POSTER Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor, with herceptin in Her-2 overexpressing breast cancer cells

European journal of cancer supplements, 2008, Vol.6 (12), p.72-72

2008

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-03-06: PTEN expression at the nexus of oncogenic signals in TNBC: Testing combination of p110beta-isoform-specific inhibitor with five PARP inhibitors

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-03-06

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-03-11: Genetic background determines the algorithm of effectiveness of targeted drugs of RAS and PI3K pathways in TNBC: Testing a combination of MEK 1/2 inhibitor with mTOR kinase inhibitor or AKT inhibitor

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-03-11

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-03-08: Preclinical evaluation of the PI3Kα/δ inhibitor, copanlisib in HER2+ breast cancer: A proof of concept study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-03-08

2019

Link zum Volltext

Verfügbarkeit prüfen

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours

British journal of cancer, 2014-08

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD8-10: APOBEC mutation signature in breast cancer correlates with tumor mutation burden and poor responses to therapy

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD8-10-PD8-10

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-03-04: Role of PTEN and BRCA1 as determinants of synergy for the combination of vistusertib with carboplatin and olaparib in TNBC

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-03-04

2018

Link zum Volltext

Verfügbarkeit prüfen

Erythropoietin to treat anaemia in patients with head and neck cancer

The Lancet (British edition), 2004-01, Vol.363 (9402), p.80-80

2004

Link zum Volltext

Verfügbarkeit prüfen

Validity of an ELISA for N-acetyltransferase-2 (NAT2) phenotyping

Journal of immunological methods, 2001-05, Vol.251 (1), p.1-9

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 191

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(178)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(43)
Science & Technology
(28)
Biological And Medical Sciences
(27)
Life Sciences & Biomedicine
(26)
Medical Sciences
(26)
Pharmacology. Drug Treatments
(21)
Female
(19)
Hematology, Oncology And Palliative Medicine
(14)
Pharmacology & Pharmacy
(13)
Animals
(12)
Antineoplastic Agents
(12)
Chemotherapy
(11)
Male
(11)
Middle Aged
(9)
Drug Evaluation
(8)
General & Internal Medicine
(8)
Medicine, General & Internal
(8)
Adult
(7)
Neoplasms - Drug Therapy
(6)
Aged
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting basal-like breast cancers

399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt–beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept study

Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial

2753 Feasibility of implementing routine genomic and proteomic profiling for advanced GYN malignancies

376 Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study

375 Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy

PP 26 IGF-1R signaling in ER+ and triple negative breast cancer - a potential target for therapy?

P068 Sequencing to identify potential targets of resistance to primary therapy

P024 Navigating genomic landscape: PI3KSIGNALING algorithm for rational combination in precision medicine

P049 Genomic landscape of the PI3K pathway and cell-cycle pathway in ER+ BC: a treatment strategy

PP 25 Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

S2 Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank

Synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and β-ionylideneacetamidobenzoates with retinoidal activity

S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer

229 POSTER Combination effects of SF1126, a vascular targeted PI3 kinase inhibitor, with herceptin in Her-2 overexpressing breast cancer cells

Abstract P2-03-06: PTEN expression at the nexus of oncogenic signals in TNBC: Testing combination of p110beta-isoform-specific inhibitor with five PARP inhibitors

Abstract P2-03-11: Genetic background determines the algorithm of effectiveness of targeted drugs of RAS and PI3K pathways in TNBC: Testing a combination of MEK 1/2 inhibitor with mTOR kinase inhibitor or AKT inhibitor

Abstract P2-03-08: Preclinical evaluation of the PI3Kα/δ inhibitor, copanlisib in HER2+ breast cancer: A proof of concept study

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours

Abstract PD8-10: APOBEC mutation signature in breast cancer correlates with tumor mutation burden and poor responses to therapy

Abstract P1-03-04: Role of PTEN and BRCA1 as determinants of synergy for the combination of vistusertib with carboplatin and olaparib in TNBC

Erythropoietin to treat anaemia in patients with head and neck cancer

Validity of an ELISA for N-acetyltransferase-2 (NAT2) phenotyping

Aktive Filter

Suchergebnisse filtern